Weider divests Haleko
This article was originally published in The Tan Sheet
Executive Summary
Weider Nutrition will sell its European subsidiary Haleko to Croatian holding company Atlantic Grupa, the firm announces June 17. Weider will receive roughly $15 mil. in exchange for the capital stock and partnership interests of Haleko's international subsidiaries, the firm adds. Haleko produces and markets brands such as Multipower and Multaben sports nutrition products. The sale allows Weider to focus on its core supplement business, specifically the Schiff Move Free line, with new product initiatives and acquisitions to complement its existing brands, the firm states. Sub-par performance by certain Haleko brands contributed to a 2% reduction in Weider's third-quarter sales and a 53% decline in earnings, the firm noted in April (1"The Tan Sheet" April 11, 2005, p. 18)...
You may also be interested in...
Weider’s Schiff Brand Hit By Escalating Raw Material Costs
Weider's joint care franchise continues to be negatively impacted by high spending on raw materials glucosamine and chondroitin
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.